Shanghai Allist Pharmaceuticals (688578.SS)

Executive Summary

Shanghai Allist Pharmaceuticals is a Chinese biopharmaceutical company publicly traded on the Shanghai Stock Exchange with a market capitalization of approximately $5.9 billion. The company is focused on developing innovative therapies for cardiovascular, metabolic, and other therapeutic areas, advancing compounds from research through commercialization. Allist currently has two commercial products and a pipeline that includes a novel TKI for non-small cell lung cancer (NSCLC) in preclinical development and a combination therapy of Furmonertinib plus Anlotinib for NSCLC that has completed Phase 2 trials. The company's robust R&D capabilities and established commercial infrastructure position it to address significant unmet medical needs in China and potentially global markets. With a strong balance sheet and a focused strategy, Allist is well-placed to drive growth through its pipeline milestones and existing product portfolio.

Upcoming Catalysts (preview)

• Q3 2026Furmonertinib + Anlotinib Phase 2 data readout or regulatory update60% success
• 2027TKI (NSCLC) preclinical to Phase 1 transition40% success
• 2026Potential new partnership or licensing deal for pipeline assets50% success